Rigel up on Phase II allergy data

RIGL was up $5.14 (38%) to $18.79 on Monday after data from a Phase II trial showed its R112 reduced the Global Nasal Allergy Symptom Score by 7 points (38%) versus 5.4 points (29%) for placebo in 319...